证券代码：603858 证券简称：步长制药 公告编号：2025-156 山东步长制药股份有限公司 第五届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届监事会第七次会议 的通知于 2025 年 8 月 15 日发出，会议于 2025 年 8 月 27 日 14 时以通讯方式召 开，应到监事 4 人，实到 4 人，会议由监事会主席王明耿先生主持。会议的出席 人数、召开和表决方式符合《中华人民共和国公司法》等法律法规及《山东步长 制药股份有限公司章程》（以下简称"《公司章程》"）的相关规定，合法有效。 与会监事经认真审议，通过如下议案： 与会监事对 2025 年半年度报告进行了认真严格的审核，并提出了如下书面 审核意见，与会监事认为： （1）公司 2025 年半年度报告的编制和审议程序符合法律、法规、《公司章 程》及公司内部管理制度的各项规定； （2）公司 2025 年半年度报告的内容和格式符合中国证监会和上海证券交易 所的各项规定，所包含的信息能全面、真 ...

Group 1 - The board of directors of Nine Company held its third meeting on August 1, 2025, with all five directors present, complying with legal and regulatory requirements [1] - The company approved its 2025 semi-annual report, which accurately reflects its financial status and operational results, with no false statements or omissions [1] - A cash dividend of 4.23 yuan (including tax) per 10 depositary receipts is proposed for distribution to all holders, subject to adjustments based on changes in the total number of depositary receipts [1] Group 2 - The board approved a special report on the use of raised funds, which complies with relevant regulations and was reviewed by the audit committee and independent directors [1] - A semi-annual evaluation report on the company's quality improvement and efficiency enhancement action plan was also approved [1] - The company plans to adjust the use of 6,000,000 depositary receipts from an employee stock ownership plan to cancellation, pending shareholder approval [1] Group 3 - The board agreed to convene the first extraordinary general meeting of 2025, with details to be announced later [1]